EGFR and lung cancer: Therapeutic benefits by the supplemental use of other biologicals to further improve survival and quality of life have become evident according to clinical trials, and some targeted agents are already used as first‐line treatment for selected patients with EGFR mutations.72, 79 Gefitinib, erlotinib and afatinib today constitute the standard of care drugs incorporated in routine clinical management of EGFR‐mutated lung cancers.